Press Releases

Date Title
Toggle Summary Kura Oncology Reports First Quarter 2020 Financial Results
– Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML – – Three abstracts accepted for presentation at ASCO, including mature data from Phase 2 study of tipifarnib in HRAS mutant HNSCC – – $216.9 million in cash, cash equivalents
Toggle Summary Kura Oncology to Report First Quarter 2020 Financial Results
SAN DIEGO , April 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report first quarter 2020 financial results after the close of
Toggle Summary Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell Lymphomas
– Second Fast Track designation for tipifarnib further highlights potential for tipifarnib to address unmet need for patients – – Company plans to initiate a registration-directed trial of tipifarnib in advanced nodal lymphomas of TFH phenotype, including AITL, in second half of 2020 – SAN DIEGO ,
Toggle Summary Kura Oncology Reports Fourth Quarter and Full Year 2019 Financial Results
– Registration-directed trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas anticipated to complete enrollment in first quarter of 2021 – – Company preparing to initiate a registration-directed trial of tipifarnib in T-cell lymphomas following positive feedback from FDA – –
Toggle Summary Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that Troy Wilson , Ph.D., J.D., President and Chief Executive Officer, is
Toggle Summary Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
SAN DIEGO , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2019 financial results after
Toggle Summary Kura Oncology Announces Transition of Chief Medical Officer
– Dr. Antonio Gualberto to step down after enabling multiple registrational strategies for tipifarnib, positioning program for success – – Clinical development, regulatory and medical affairs veteran Dr. Bridget Martell named acting Chief Medical Officer – – Dr.
Toggle Summary Kura Oncology to Present at J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced its participation at the 38th Annual J.P. Morgan Healthcare Conference .
Toggle Summary Kura Oncology Appoints Kirsten Flowers as Chief Commercial Officer
Company strengthens leadership team to support pre-commercial efforts and launch optimization SAN DIEGO , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer,
Toggle Summary Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN Trial
– Fast Track designation highlights potential for tipifarnib to address unmet need for patients with HRAS mutant HNSCC – – Registration-directed AIM-HN trial expected to complete enrollment in first quarter of 2021 – SAN DIEGO , Dec. 16, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.